CERRI, SILVIA
 Distribuzione geografica
Continente #
NA - Nord America 1.540
AS - Asia 869
EU - Europa 850
SA - Sud America 121
AF - Africa 21
OC - Oceania 5
Totale 3.406
Nazione #
US - Stati Uniti d'America 1.515
CN - Cina 385
IE - Irlanda 264
SG - Singapore 228
HK - Hong Kong 138
RU - Federazione Russa 138
DE - Germania 104
BR - Brasile 99
FI - Finlandia 84
IT - Italia 78
VN - Vietnam 40
GB - Regno Unito 37
UA - Ucraina 37
SE - Svezia 20
CZ - Repubblica Ceca 19
CA - Canada 18
IN - India 18
FR - Francia 17
JP - Giappone 10
AR - Argentina 9
AT - Austria 8
BD - Bangladesh 8
IQ - Iraq 8
ZA - Sudafrica 8
ES - Italia 7
NL - Olanda 7
PL - Polonia 7
BE - Belgio 6
MX - Messico 6
LT - Lituania 5
MA - Marocco 5
MU - Mauritius 5
AU - Australia 4
AZ - Azerbaigian 3
CO - Colombia 3
ID - Indonesia 3
KR - Corea 3
TR - Turchia 3
UY - Uruguay 3
CH - Svizzera 2
CL - Cile 2
EG - Egitto 2
GE - Georgia 2
KG - Kirghizistan 2
LK - Sri Lanka 2
OM - Oman 2
PE - Perù 2
PK - Pakistan 2
PY - Paraguay 2
SA - Arabia Saudita 2
SK - Slovacchia (Repubblica Slovacca) 2
AE - Emirati Arabi Uniti 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
EE - Estonia 1
HU - Ungheria 1
IL - Israele 1
IS - Islanda 1
JO - Giordania 1
KH - Cambogia 1
KW - Kuwait 1
MD - Moldavia 1
MK - Macedonia 1
MR - Mauritania 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
RS - Serbia 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
UZ - Uzbekistan 1
Totale 3.406
Città #
Chandler 289
Dublin 264
Dallas 169
Ashburn 162
Hong Kong 137
Beijing 114
Singapore 103
Boardman 58
Helsinki 54
Los Angeles 46
Jacksonville 45
Princeton 45
Lawrence 44
New York 44
Shanghai 37
Munich 36
Medford 33
Wilmington 30
Nanjing 23
The Dalles 20
São Paulo 19
Buffalo 18
Chicago 18
Moscow 18
Redondo Beach 18
Brno 16
Ho Chi Minh City 15
Nanchang 14
Changsha 13
Milan 13
Shenyang 13
Washington 12
Pavia 11
Tianjin 11
Hebei 10
Rome 10
Tokyo 10
Turku 10
Atlanta 9
Fairfield 9
Hangzhou 9
Santa Clara 9
Hanoi 8
Jiaxing 8
Columbus 7
Düsseldorf 7
London 7
Nuremberg 7
Orem 7
Stockholm 7
Warsaw 7
Brooklyn 6
Brussels 6
Chennai 6
Denver 6
Johannesburg 6
Norwalk 6
Seattle 6
Toronto 6
Boston 5
Guangzhou 5
Montreal 5
New Delhi 5
Phoenix 5
Rio de Janeiro 5
Shijiazhuang 5
Falls Church 4
Giessen 4
Manchester 4
Ningbo 4
Piscataway 4
Woodbridge 4
Baku 3
Florence 3
Las Vegas 3
Mexico City 3
Montevideo 3
Poplar 3
San Francisco 3
Wuhan 3
Xi'an 3
Amsterdam 2
Ankara 2
Ann Arbor 2
Bishkek 2
Bratislava 2
Cairo 2
Calgary 2
Cambridge 2
Campinas 2
Campo Mourão 2
Carney 2
Caxias do Sul 2
Charlotte 2
Colombo 2
Des Moines 2
Elk Grove Village 2
Falkenstein 2
Guarulhos 2
Houston 2
Totale 2.275
Nome #
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 110
Immediate early genes regulation in rat cerebellar cortex during long-term synaptic plasticity induction. 109
Activation of the CREB/c-Fos Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer 105
Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: Relevance to gastrointestinal dysfunctions in Parkinson's disease 105
Interaction between the cellular prion (PrPC) and the 2P domain K+ channel TREK-1 protein. 105
Postnatal development of Central Nervous System: anomalies in the formation of cerebellum fissures 98
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 97
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 95
Effects of cisplatin on neuronal cell B50: involvement of mitochondria in apoptosis induction. 93
Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease 92
Cell proliferation and death in the brain of active and hibernating frogs 89
Developmental neurotoxicity study of platinum compounds. Effects of cisplatin versus a novel Pt(II) complex on rat cerebellum 88
Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: Comparative study with conventional in vivo techniques in the rat 87
An update on the use of non-ergot dopamine agonists for the treatment of Parkinson’s disease 87
In vivo imaging of early signs of dopaminergic neuronal death in an animal model of Parkinson's disease 83
Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson's disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol 81
Inefficient DNA Repair Is an Aging-Related Modifier of Parkinson's Disease 81
The insect brain as a model to investigate the PCB effects. Changes of NOS-dependent NADPH diaphorase activity in Blattella germanica 80
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease 78
Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease 78
Gba mutations influence the release and pathological effects of small extracellular vesicles from fibroblasts of patients with parkinson’s disease 77
Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity 76
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 75
Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects 74
Repurposing opportunities for Parkinson’s disease therapies 74
Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease 73
Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat 72
Mitochondrial Complex i Reversible S-Nitrosation Improves Bioenergetics and Is Protective in Parkinson's Disease 71
Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease 70
Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine 69
Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease 69
Interactions of neurotransmitter systems during postnatal development of the rat hippocampal formation: effects of cisplatin 68
Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease 66
Pathological remodelling of colonic wall following dopaminergic nigrostriatal neurodegeneration 66
Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinson’s disease 65
The exosomal/total α-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients 63
Potential therapeutic effects of polyphenols in Parkinson's disease: In vivo and in vitro pre-clinical studies 61
Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: Implications for reparative therapy in Parkinson's disease 54
Impaired Mitochondrial Respiration in REM-Sleep Behavior Disorder: A Biomarker of Parkinson's Disease? 44
Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias 43
Peripheral-central neuroimmune crosstalk in parkinson’s disease: What do patients and animal models tell us? 39
Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease 39
Parkinson's Disease in Women and Men: What's the Difference? 38
Role of autophagy in Parkinson’s disease 35
Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells 35
In vivo modeling of prodromal stage of Parkinson's disease 34
Investigation and Comparison of Active and Passive Encapsulation Methods for Loading Proteins into Liposomes 31
Parkinson’s disease 26
LC-MS/MS-Based Determination of Ambroxol in Human Plasma and Cerebrospinal Fluid: Validation and Applicability in a Phase II Study on GBA-Associated Parkinson’s Disease Patients 19
Totale 3.467
Categoria #
all - tutte 17.190
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.190


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202184 0 0 0 0 0 11 0 21 23 16 9 4
2021/2022189 0 1 3 0 1 5 2 11 10 0 33 123
2022/2023757 91 80 15 55 58 62 0 41 328 3 17 7
2023/2024362 54 50 14 15 27 96 20 22 6 14 28 16
2024/2025862 48 64 28 21 21 60 42 53 210 48 119 148
2025/2026927 134 118 207 194 259 15 0 0 0 0 0 0
Totale 3.467